Evidence map›Paper›PMID 38904912›Full record

ReviewJournal of pharmacokinetics and pharmacodynamics2024

Advancing cancer drug development with mechanistic mathematical modeling: bridging the gap between theory and practice.

Alexander Kulesza, Claire Couty, Paul Lemarre, Craig J Thalhauser, Yanguang Cao

Abstract readReview
In one paragraph

Review in Journal of pharmacokinetics and pharmacodynamics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Alexander KuleszaNovadiscovery, 1 Place Giovanni Verrazzano, 69009, Lyon, France. mail@alexanderkulesza.de.
Claire CoutyNovadiscovery, 1 Place Giovanni Verrazzano, 69009, Lyon, France.
Paul LemarreNovadiscovery, 1 Place Giovanni Verrazzano, 69009, Lyon, France.
Craig J ThalhauserGenmab US, Inc., 777 Scudders Mill Rd Bldg 2 4th Floor, Plainsboro, NJ, 08536, USA.
Yanguang CaoDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.

Funding

Quantitative Systems Pharmacology of Antibody Therapeutics across Diverse Biological ContextsR35GM152449 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Yanguang Cao · 2024 to 2026
$1.2M
NIGMS NIH HHS R35 GM152449
6 · The paper itself

Abstract

Quantitative predictive modeling of cancer growth, progression, and individual response to therapy is a rapidly growing field. Researchers from mathematical modeling, systems biology, pharmaceutical industry, and regulatory bodies, are collaboratively working on predictive models that could be applied for drug development and, ultimately, the clinical management of cancer patients. A plethora of modeling paradigms and approaches have emerged, making it challenging to compile a comprehensive review across all subdisciplines. It is therefore critical to gauge fundamental design aspects against requirements, and weigh opportunities and limitations of the different model types. In this review, we discuss three fundamental types of cancer models: space-structured models, ecological models, and immune system focused models. For each type, it is our goal to illustrate which mechanisms contribute to variability and heterogeneity in cancer growth and response, so that the appropriate architecture and complexity of a new model becomes clearer. We present the main features addressed by each of the three exemplary modeling types through a subjective collection of literature and illustrative exercises to facilitate inspiration and exchange, with a focus on providing a didactic rather than exhaustive overview. We close by imagining a future multi-scale model design to impact critical decisions in oncology drug development.

Indexed as

Antineoplastic AgentsDrug DevelopmentNeoplasmsAnimalsHumansModels, BiologicalModels, TheoreticalSystems BiologyAntineoplastic AgentsEcologic and evolutionary modelingImmuno-oncologyModel informed drug developmentModeling & simulationOncologyTumor growth inhibition models

Identifiers

PMID38904912
PMCPMC11795844

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.